Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 3 min ago
Peer-reviewedCC BYBiomedicines

Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts

  • Holger N. Lode1
  • Przemysław Holko2
  • Aleksandra Wieczorek3
  • Katarzyna Śladowska2
  • Nikolai Siebert1
  • Dominique Valteau-Couanet4
  • Alberto Garaventa5
  • Adela Cañete6
  • John Anderson7
  • Isaac Yaniv8
  • Shifra Ash8
  • Lucas Moreno9
8 more authors
  • Juliet Gray10
  • Roberto Luksch11
  • Genevieve Laureys12
  • Cormac Owens13
  • Carla Manzitti5
  • Sascha Troschke-Meurer1
  • Paweł Kawalec2
  • Ruth L. Ladenstein14
14 affiliations
  1. 1Department of Pediatric Hematology and Oncology, University Medicine Greifswald, 17475 Greifswald, Germany
  2. 2Department of Nutrition and Drug Research, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, 31-008 Krakow, Poland
  3. 3Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, 31-008 Krakow, Poland
  4. 4Children and Adolescent Oncology Department, Gustave Roussy, Paris-Sud University, 94805 Paris, France
  5. 5Oncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy
  6. 6Hospital Universitario y Politecnico La Fe, 46026 Valencia, Spain
  7. 7UCL Great Ormond Street Institute of Child Health, London WC1N 1EH, UK
  8. 8Schneider Children’s Medical Center of Israel, Petach Tikva 4920235, Israel
  9. 9Division of Pediatric Hematology & Oncology, Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d’Hebron 119, 08035 Barcelona, Spain
  10. 10Centre for Cancer Immunology, University of Southampton, Southampton SO16 6YD, UK;
  11. 11Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
  12. 12Department of Pediatric Hematology/Oncology and Stem Cell Transplantation, Ghent University Hospital, 9000 Ghent, Belgium;
  13. 13Department of Haematology and Oncology, Children’s Health Ireland, D12 N512 Dublin, Ireland
  14. 14St. Anna Children’s Hospital, St. Anna Children’s Cancer Research Institute and Department of Pediatrics, Medical University Vienna, 1090 Vienna, Austria
Read full textPDFCite

Related

  1. Chidamide combined with dinutuximab beta, irinotecan and temozolomide for relapsed or refractory neuroblastoma in children: protocol for a prospective, single-centre, open-label, single-arm, phase II study in China
    Yan Jin, Benfu Zhong, Jiarun Fu +14
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textOncologyCrossrefPMC
  2. Overall survival after relapse in high-risk neuroblastoma: an adjusted indirect comparison of post-relapse dinutuximab beta, historical controls, and relapse after first-line dinutuximab beta maintenance.
    Holger N Lode, Przemysław Holko, Aleksandra Wieczorek +17
    Frontiers in oncologyPeer-reviewedCC BYFull textNeurologyEurope PMCCrossref
  3. Development and Optimization of 111In-Dinutuximab-IRDye800, a Dual-Modality Intraoperative Molecular Imaging Agent for Pediatric Neuroblastoma Resection
    C. Y. Yip, L. T. Rosenblum, A. Pant +13
    bioRxivPreprintCC BYFull textOncologybioRxiv
  4. Flow Cytometric Detection of Bone Marrow Cell Populations Phenotypically Compatible with Neuroblastoma: An Exploratory Comparison with Conventional Methods
    Karolina Bukowska-Strakova, Marta Surman, Izabela Siemińska +9
    CancersPeer-reviewedCC BY 4.0Full textNeurologyCrossrefEurope PMC
  5. Exploratory Profiling of ABC-Family Genes Identifies a Candidate Score in Pediatric Neuroblastoma
    HITOMI MOTOMURA, KAZUNORI AKIMOTO, SHINGO YAMAZAKI
    Cancer Genomics & ProteomicsPeer-reviewedCC BY-NC-ND 4.0Full textNeurologyPMC

Cite

BibTeXRIS
BibTeX
@article{lode2026survival,
  title = {{Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts}},
  author = {Holger N. Lode and Przemysław Holko and Aleksandra Wieczorek and Katarzyna Śladowska and Nikolai Siebert and Dominique Valteau-Couanet and Alberto Garaventa and Adela Cañete and John Anderson and Isaac Yaniv and Shifra Ash and Lucas Moreno and Juliet Gray and Roberto Luksch and Genevieve Laureys and Cormac Owens and Carla Manzitti and Sascha Troschke-Meurer and Paweł Kawalec and Ruth L. Ladenstein},
  journal = {Biomedicines},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13701175},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Survival Outcomes with IL-2-Free Dinutuximab Beta Treatment Strategies With or Without 13-cis-Retinoic Acid in Relapsed or Refractory Neuroblastoma: An Exploratory Unanchored, Population-Adjusted Comparison of Two Prospective Cohorts
AU  - Holger N. Lode
AU  - Przemysław Holko
AU  - Aleksandra Wieczorek
AU  - Katarzyna Śladowska
AU  - Nikolai Siebert
AU  - Dominique Valteau-Couanet
AU  - Alberto Garaventa
AU  - Adela Cañete
AU  - John Anderson
AU  - Isaac Yaniv
AU  - Shifra Ash
AU  - Lucas Moreno
AU  - Juliet Gray
AU  - Roberto Luksch
AU  - Genevieve Laureys
AU  - Cormac Owens
AU  - Carla Manzitti
AU  - Sascha Troschke-Meurer
AU  - Paweł Kawalec
AU  - Ruth L. Ladenstein
PY  - 2026
DA  - 2026/09/29
JO  - Biomedicines
UR  - https://europepmc.org/article/PMC/PMC13701175
SN  - 2227-9059
ER  -